Compass Pathways Stock

Compass Pathways Accounts Payable

The Accounts Payable of Compass Pathways (CMPS) as of Sep 4, 2026 is 15.22 M USD. In the previous year, Accounts Payable was 12.28 M USD — a change of 23.93% (higher).

Accounts Payable

15.22 MUSD

YoY

23.93%

Last updated:

Accounts Payable of Compass Pathways is 2026 15.22 M USD. Accounts Payable of Compass Pathways was 2025 12.28 M USD. It decreases by 23.93% higher compared to the previous year.

The Compass Pathways Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
694,000.00 USD
Jan 1, 2019
1.33 M USD
Jan 1, 2020
2.75 M USD
Jan 1, 2021
2.56 M USD
Jan 1, 2022
4.76 M USD
Jan 1, 2023
5.89 M USD
Jan 1, 2024
12.28 M USD
Jan 1, 2025
15.22 M USD
The Compass Pathways Accounts Payable history
YEARAccounts PayableYoY
15.22 MUSD+23.93%
12.28 MUSD+108.47%
5.89 MUSD+23.76%
4.76 MUSD+85.69%
2.56 MUSD-6.66%
2.75 MUSD+107.32%
1.33 MUSD+90.92%
694,000.00USD
Access this data via the Eulerpool API

Compass Pathways Stock analysis

What does Compass Pathways do? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compass Pathways stock

Accounts Payable of Compass Pathways is 15.22 M USD in 2026.

Accounts Payable of Compass Pathways changed from 12.28 M USD to 15.22 M USD, representing a 23.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Compass Pathways since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Compass Pathways historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Compass Pathways

All Key Metrics — Compass Pathways